Tedizolid: A novel oxazolidinone for gram-positive infections

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Moellering, Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

linezolid; methicillin resistant S. aureus; oxazolidinones; tedizolid

Indexed keywords

TEDIZOLID;

ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING SITE; DEPRESSION; GRAM POSITIVE INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SKIN INFECTION;

LINEZOLID; METHICILLIN-RESISTANT S. AUREUS; OXAZOLIDINONES; TEDIZOLID;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES;

EID: 84892155440     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit658     Document Type: Article

References (16)

1. Moellering RC Jr. MRSA: The first half century. J Antimicrob Chemother 2012; 67:4-11
2. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-87
3. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011; 52:99-114
4. Mera RM, Suaya JA, Madsen HA, et al. Disproportionate increase from 2004-2008 in S. aureus associated US hospitalisation rates in children. In: Program and Abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases/27th International Congress of Chemotherapy, Milan, Italy, 2011:129. Abstract P1219
5. Gardner P, Smith DH, Beer H, Moellering RC Jr. Recovery of resistance (R) factors from a drug-free community. Lancet 1969; 2:774-6
6. D'Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature 2011; 477:457-61
7. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12
8. Moellering RC Jr. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011; 37:2-9
9. Ford CW, Hamel JC, Stapert D, et al. Oxazolidinones: New antibacterial agents. Trends Microbiol 1997; 5:196-200
10. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Des 1996; 2:175-94
11. Moellering RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:155-7
12. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45
13. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012; 56:603-12
14. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Molec Microbiol 2007; 64:1506-14
15. Shen J, Wang Y, Schwarz S. Presence and dissemination of the multiresistance gene cfr in gram-positive and gram-negative bacteria. J Antimicrob Chemother 2013; 68:1697-706
16. Baos E, Candel FJ, Merino P, Pena I, Picazo JJ. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76:325-9